TG Therapeutics
TGTX
115 hedge funds and large institutions have $200M invested in TG Therapeutics in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 43 increasing their positions, 27 reducing their positions, and 27 closing their positions.
105% more call options, than puts
Call options by funds: $4.51M | Put options by funds: $2.2M
59% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 27
1.42% more ownership
Funds ownership: 57.56% → 58.98% (+1.4%)
9% less funds holding
Funds holding: 127 → 115 (-12)
25% less capital invested
Capital invested by funds: $267M → $200M (-$66.5M)
41% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
+$7.96M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.22M |
| 3 |
Two Sigma Investments
New York
|
+$2.9M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$2.73M |
| 5 |
Renaissance Technologies
New York
|
+$2.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$10.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.36M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2.9M |
| 4 |
NC
Nexthera Capital
New York
|
-$2.49M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.49M |
TGTX Hedge Fund Activity: Q4 2018 in Review
115 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2018, worth a combined $200M — down 25% from $267M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of TGTX and 16 opened new positions — a net loss of 11 holders — while 27 trimmed existing stakes and 43 added.
The largest buyer was Bridger Management, adding an estimated $7.96M. The largest seller was Franklin Resources, exiting entirely with an estimated $10.6M sold.
- 115 institutional investors held TG Therapeutics (TGTX) as of Q4 2018, down from 127 in Q3 2018.
- Funds reported $200M of TG Therapeutics stock for Q4 2018, down 25% quarter-over-quarter.
- 16 funds opened new TG Therapeutics positions in Q4 2018 and 27 closed out, a net change of -11 holders.
- The largest TG Therapeutics buyer in Q4 2018 was Bridger Management, an estimated $7.96M added.
- The largest TG Therapeutics seller in Q4 2018 was Franklin Resources, an estimated $10.6M sold.
Based on aggregated 13F filings for Q4 2018.